New HIV vaccines enter human safety trials
NCT ID NCT03878121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests three new HIV vaccines in healthy adults aged 18-49 to see if they are safe and trigger an immune response. Two vaccines are given as nasal sprays, followed by a booster shot. The trial also monitors household and intimate contacts to check if the vaccine viruses spread. The goal is to gather early safety data for a potential HIV prevention strategy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?